HER2 Alterations in Non-Small Cell Lung Cancer : Episode 3
Liquid vs Solid Tumor Biopsies in NSCLC
Mark A. Socinski, MD, debates the merits of liquid versus tissue tumor biopsies in NSCLC biomarker testing.
EP: 1.Biomarker Testing in NSCLC: Clinical Scenario
EP: 2.Approaches to Biomarker Testing in NSCLC
Now Viewing
EP: 3.Liquid vs Solid Tumor Biopsies in NSCLC
EP: 4.HER2 Alterations in NSCLC: Clinical Scenario
EP: 5.The Role of HER2 Alterations in NSCLC
EP: 6.Testing Patients with NSCLC for HER2 Mutations
EP: 7.Current Treatment Options in NSCLC
EP: 8.Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC
EP: 9.HER2-Targeted Therapies in NSCLC
EP: 10.Major Adverse Events of Anti-HER2 Therapies
EP: 11.Unmet Needs in NSCLC Therapy
EP: 12.Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC
EP: 13.Novel HER2-Targeted Therapies for NSCLC
Related Videos
Related Content
